Depression and Anxiety Trial, Recruiting NCT06004414 Sponsor: NYU Langone Health Condition: Depression and Anxiety
Back to Depression And Anxiety

Depression and Anxiety Trial, Recruiting

NCT06004414
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are currently enrolled in high school (for the first phase) or specifically in 9th through 11th grade (for the main study phase)
  • People who score 10 or higher on a standard anxiety questionnaire (GAD-7) or a standard depression questionnaire (PHQ-9)
  • People who can read and speak English, as the digital program used in this study is only available in English
  • People enrolled at one of the official study locations (for the main study phase only)

Who may not be able to join:

  • People who do not own or use a smartphone
  • People who are already receiving mental health treatment at one of the study sites within one month before joining (this applies to the main study phase)
  • People showing symptoms of mania or psychosis, as the digital program used in this study has not been tested with people experiencing serious mental illness — the trial site would refer these individuals to more intensive care
  • People who are currently having thoughts of suicide with a specific plan and intention to act on it — the trial site would refer these individuals to a crisis or suicide risk support service, and eligibility would only be reconsidered once those thoughts have passed

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Anna Van Meter, PhD, NYU Langone Health

Phone: 646-754-5085

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
8 February 2024
Est. completion
31 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in Patient Health Questionnaire-9 (PHQ-9) Score; Change in General Anxiety Disorder-7 (GAD-7) Score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov